Search research articles
Contact Us
Filters
Showing results (41-50 of 48) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 48 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
J P Stevenson, K S Yao, M Gallagher, et al.
Oncogene
|
June 23, 2015
Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism
C R Goodman, T Sato, A R Peck, et al.
Nanoscale
|
March 9, 2018
Dynamic self-assembly of DNA minor groove-binding ligand DB921 into nanotubes triggered by an alkali halide
R Mizuta, J M Devos, J Webster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2013
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
A L Cohn, J Tabernero, J Maurel, et al.
British Journal of Cancer
|
March 18, 2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
E Van Cutsem, P M Hoff, P Harper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri, X V Wang, V Makker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]
K L Jhaveri, X V Wang, V Makker, et al.
NPJ Precision Oncology
|
March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
A S Mansfield, Z Wei, R Mehra, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 48) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 48 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 24, 1999
Phase I clinical/pharmacokinetic and pharmacodynamic trial of the c-raf-1 antisense oligonucleotide ISIS 5132 (CGP 69846A)
J P Stevenson, K S Yao, M Gallagher, et al.
Oncogene
|
June 23, 2015
Steroid induction of therapy-resistant cytokeratin-5-positive cells in estrogen receptor-positive breast cancer through a BCL6-dependent mechanism
C R Goodman, T Sato, A R Peck, et al.
Nanoscale
|
March 9, 2018
Dynamic self-assembly of DNA minor groove-binding ligand DB921 into nanotubes triggered by an alkali halide
R Mizuta, J M Devos, J Webster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 21, 2013
A randomized, placebo-controlled phase 2 study of ganitumab or conatumumab in combination with FOLFIRI for second-line treatment of mutant KRAS metastatic colorectal cancer
A L Cohn, J Tabernero, J Maurel, et al.
British Journal of Cancer
|
March 18, 2004
Oral capecitabine vs intravenous 5-fluorouracil and leucovorin: integrated efficacy data and novel analyses from two large, randomised, phase III trials
E Van Cutsem, P M Hoff, P Harper, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
September 11, 2019
Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q
K L Jhaveri, X V Wang, V Makker, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 8, 2021
Corrigendum to 'Ado-trastuzumab emtansine (T-DM1) in patients with HER2-amplified tumors excluding breast and gastric/gastroesophageal junction (GEJ) adenocarcinomas: results from the NCI-MATCH trial (EAY131) subprotocol Q': [Annals of Oncology 30 (2019) 1821-1830]
K L Jhaveri, X V Wang, V Makker, et al.
NPJ Precision Oncology
|
March 2, 2022
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial
A S Mansfield, Z Wei, R Mehra, et al.
Page
of 5